Understanding how special immune cells called Tc9 can destroy tumors
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells
This research explores how a unique type of immune cell, called Tc9 cells, can effectively kill cancer cells by triggering a specific kind of cell death.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11141628 on NIH RePORTER |
What this research studies
Our immune system has different types of T cells, and this project focuses on a special kind called Tc9 cells, which release a substance called IL-9. We've seen that these Tc9 cells are better at fighting tumors than other T cells. This work aims to understand exactly how Tc9 cells cause cancer cells to die through a process called pyroptosis, which is a powerful form of programmed cell death. By learning more about this process, we hope to find new ways to make cancer treatments more effective.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit future cancer patients who might receive advanced immune cell therapies.
Not a fit: Patients seeking immediate treatment options would not directly benefit from this early-stage laboratory research.
Why it matters
Potential benefit: If successful, this work could lead to new and more powerful cell-based therapies for cancer patients by enhancing the body's natural ability to fight tumors.
How similar studies have performed: Preliminary studies have shown that Tc9 cells have a stronger anti-tumor effect compared to other T cells, suggesting promise for this novel approach.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Yi, Qing — Methodist Hospital Research Institute
- Study coordinator: Yi, Qing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.